David A. Siegel Amylyx Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 309,500 shares of AMLX stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
309,500
Previous 1,154,200
73.18%
Holding current value
$1.26 Million
Previous $2.19 Million
54.29%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$18.9 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$12.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$10.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$8.65 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$8.24 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $238M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...